Dihydroergocryptine
| Systematic (IUPAC) name | |
|---|---|
| (2R,4R,7R)-N- [(1S,2S,4R,7S)- 2-hydroxy- 7-(2-methylpropyl)- 5,8-dioxo- 4-(propan-2-yl)- 3-oxa- 6,9-diazatricyclo [7.3.0.02,6]dodecan-4-yl]- 6-methyl- 6,11-diazatetracyclo [7.6.1.02,7.012,16] hexadeca- 1(16),9,12,14-tetraene- 4-carboxamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 25447-66-9 |
| ATC code | N04BC03 |
| PubChem | CID 114948 |
| ChemSpider | 102887 |
| UNII | 67V3FSL2GL |
| ChEBI | CHEBI:59919 |
| Synonyms | 12'-Hydroxy- 2'-(1-methylethyl)- 5'α-(2-methylpropyl)- 9,10α-dihydroergotaman- 3',6',18-trione; OR (5'α,10α)-9,10-dihydro- 12'-hydroxy-2'- (1-methylethyl)- 5'-(2-methylpropyl)- ergotaman- 3',6',18-trione |
| Chemical data | |
| Formula | C32H43N5O5 |
| Mol. mass | 577.715 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
Dihydroergocryptine is a dopamine agonist of the ergoline chemical class used as an antiparkinson agent.
[edit] References
|
|
|
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |

